Several Myeloma Institute for Research and Therapy (MIRT) patients have contacted me, concerned that world renowned myeloma specialist, Dr. Bart Barlogie, may be leaving UAMS in Little Rock. I’m having trouble getting a clear picture of what’s really happening. Apparently the split is contentious; not sure if he’s being forced out or asked to leave.
I heard that Dr. Bart Barlogie was retiring. Is it true? No. But according to the Associated Press, Dr. Barlogie is resigning as head of Little Rock's Myeloma Institute for Research and Therapy (MIRT): London Doctor to lead UAMS cancer Center LITTLE ROCK — A London doctor has been tapped to serve as the new
It has been a crazy busy day! I spent the morning working with my landscape contractor. Then the afternoon getting blood work, meeting with my local medical oncologist and undergoing radiation therapy. Needless to say I'm wiped tonight! Our air conditioning conked out over the holiday weekend. No parts available until today. The good news
Dr. Bart Barlogie is a myeloma legend. Love him or hate him, his unbridled obsession for finding a multiple myeloma cure has been relentless. The father of Total Therapy, Dr. Barlogie has helped the University of Arkansas Medical School (UAMS) develop one of the world's foremost multiple myeloma treatment centers, known as the Myeloma Institute
With few exceptions, most myeloma specialists don't believe that our cancer can be cured using therapy options available today. These exceptions include a small percentage (5-10%) of allogeneic (donor) transplant recipients, and possibly some low risk, Total Therapy grads from Arkansas. Any others are considered outliers; rare exceptions that don't fit the norm. Five years
Last month I was featured in a Nature Magazine article about multiple myeloma and stem cell transplants: Stem cells: Transplants on trial By Elie Dolgin They included this handsome picture, too! Point of fact, the photo editors--located in England--flipped the captions of the two pictures I sent them. The actual stem cell infusion pic was
Did you happen to notice Kate's insightful comment earlier this week about Wednesday's Post? I thought it was worth a second look: Pat, I look forward to hearing those 2nd and 3rd opinions. I hope you include your process in selecting those docs as opposed to Mayo, Dana Farber etc. I'm glad you reminded me,
There was a very large controversy last December at ASH in Orlando. Two studies which followed long-term Revlimid users found they had an 8% risk of developing a form of Acute Myeloid Leukemia (AML).Revlimid is manufactured by Celgene Pharmaceuticals, a publicly traded company. This news caused Celgene's stock to crash and rumors to explode in
Exciting New Multiple Myeloma Therapy Study Overview Published In Blood: Union Of Forces Advances Myeloma Care
While attending an International Myeloma Foundation (IMF) Patient and Family Seminar last fall in Minneapolis, I met an impressive, young myeloma doc and researcher on the rise, Mayo Clinic's Dr. Kieth Stewart. I felt he had a very reasonable and balanced approach to myeloma therapy. Here is a research paper the prestigious hematological publication, Blood,
Yesterday I shared part of my conversation/interview with Dr. Ravi Vij, a multiple myeloma specialist with the University of Washington School of Medicine. The conversation centered on the University of Arkansas Medical Center's intense research into classifying and treating high risk myeloma.Here is a link to the American Society of Clinical Oncology (ASCO) Data Base, connecting
Before we move on, I wanted to share some of Dr. Ravi Vij's thoughts about UAMS—the University of Arkansas Medical Center. Myeloma docs and researchers there have been developing an aggressive form of anti-myeloma treatment called Total Therapy (TT). Arkansas myeloma specialist, Dr. Barlogie, and other UAMS myeloma researchers are best known for helping newly
Let's take a break in the ongoing debate over which myeloma therapy approach to take and focus on the future. I am currently logged-on to an interesting and timely teleconference with Dr. Brian Durie, Medical Director of the International Myeloma Foundation. Dr. Durie is previewing the myeloma related studies which will be presented at the
I feel strongly that this debate about the purpose and effectiveness of different multiple myeloma therapies is more than an academic exercise. The more any myeloma patient can learn about his or her therapy options, the better chance they will select the therapy option which is most effective for them. Here is part two of
Immediately after writing my last post I contacted a good friend, Nick van Dyk, who is currently a patient at Arkansas. You remember Nick, right? I posted his story here a few weeks ago. A tandem transplant recipient, Nick was more than happy to share his thoughts about the discrepancies in data I seem to
Nick has generously agreed to help educate us about Total Therapy. This is a new concept for me, but I know some of you are familiar with this treatment philosophy. Nick wrote this yesterday:As for getting primed about Total Therapy, I would refer you via google to a powerpoint presentation called "The Myth of Incurability."